Unfortunately Kevin revenue and profit will dive in 2025 and...

Unfortunately Kevin revenue and profit will dive in 2025 and 2026. No one likes to acknowledge it but the only catalyst for revenue will be trial progression as the company's earnings will reduce this year and next year, as will their underlying profit. You can probably expect a SP reversal if trials progress. However, the return on those won't be seen for several years. Another blow was the October FDA meeting, which was anticipated for about 9 months to be a catalyst and to propel NEU to their next stage. Unfortunately NEU and FDA couldn't reach alignment what endpoints NEU would use in their trials. Management indicated they were positive and hopeful agreement would be reached by Christmas. Shortly after that, CEO appeared on a podcast and did not sound optimistic about time frame for alignment. Now Christmas has came and gone without an announcement. The primary announcement since then was about a share buy back. According to posters on this forum who claim be be in control of a large percentage of shares, he and his associates were pressuring management for the buy back for weeks leading up to that announcement. While there's no indication their lobbying worked, it seems to be an amazing coincidence that the company announced a buy back right around the time that poster was making these comments. That poster can be looked up, their business name and their associates have large holdings in na number of small companies in AUS. While I'm sure everything is above board, it raises some questions, particularly when large holders who may be looking to sell often have a lot of self interest in buy backs occuring. Since the buy back was announced the SP has gone south and that poster is no longer posting.